Skip to content
OVistoaIntelligence index
AboutMethodologyPricingDocs
Sign inSign up
BREAKINGPerson found dead in car after it plows into health club in Portland, Oregon2 hr ago
Top StoriesUnited StatesCanadaWorldPoliticsGeneralBusinessTechHealthSportsAviationArtificial IntelligencePublishers

New Therapies for Chronic Spontaneous Urticaria Expand Options Beyond Anti-IgE Care

1 articles · 1 outlets · spread 0.00

New Therapies for Chronic Spontaneous Urticaria Expand Options Beyond Anti-IgE Care
healthcare2 d ago

New Therapies for Chronic Spontaneous Urticaria Expand Options Beyond Anti-IgE Care

Full coverage view across outlets, lean, source quality, and framing. Compare framing without algorithmic ranking.

1 articles1 outletsSpread 0.008 claims
OVistoa

Article-level news analysis, transparent scoring, and API tools for readers, publishers, and teams that need source context.

DMCA and copyright review

Copyright owners can submit notices, counter-notices, and source material concerns through the dedicated review flow.

Open DMCA review

Product

  • Home
  • Feed
  • Search
  • Topics
  • Saved

Platform

  • About
  • Methodology
  • Home
  • Search
  • Saved
  • Me

From the Left

0 outlets

No coverage from this perspective yet.

From the Center

1 outlet
  • MedPage Today·May 1

    New Therapies for Chronic Spontaneous Urticaria Expand Options Beyond Anti-IgE Care

    — Dermatologists can now take more control of treating CSU patients, says Gil Yosipovitch by Gregory Laub, Senior Director, Video, MedPage Today May 1, 2026 • 1 min read Discussions at the American Academy of Dermatology annual meeting highlighted a rapidly evolving treatment landscape for chronic spontaneous urticaria (CSU), with new targeted therapies expanding options beyond traditional antihistamines and anti-immunoglobulin E (IgE) approaches. In this exclusive MedPage Today video, Gil Yosipovitch, MD, of the University of Miami Miller School of Medicine, reflects on the past year of approvals and what they mean for dermatologists taking a more central role in managing CSU. Following is a transcript of his remarks: So big, major advances have occurred in the last year with approval of two drugs that target the neuroimmune system and mast cells. One that we are all familiar [with] as dermatologists because it's been in the market for the last 10 years is dupilumab (Dupixent). It is a biologic injectable targeting the IL [interleukin]-4 receptor and this cascade affects the neuroimmune aspect of chronic urticaria. And second is a drug that targets the mast cell that is an oral medication, remibrutinib (Rhapsido), which is a Bruton's tyrosine kinase [inhibitor]. And

From the Right

0 outlets

No coverage from this perspective yet.

Claim synthesis

Pro users see canonical claims across the cluster and which outlets reported each one.

Learn more

Outlets covering this story

MedPage Today

First seen

May 1, 2026

Latest

May 1, 2026

Outlets

1

Diversity

100/100

  • Pricing
  • API docs
  • Publishers

    • Account

    • Sign in
    • Create account
    • Reader settings
    • API console

    Legal

    • Terms
    • Privacy
    • Security
    • DMCA

    © 2026 Vistoa. All rights reserved.

    Limited excerpts, attribution, analysis, and outbound publisher links remain core product boundaries.